Genentech announced on December 6 that the FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations. . The approval is based on data from a multicenter, open-label, randomized, controlled… Continue Reading Roche PD-L1 first-line therapy for lung cancer

EvaluatePharma’s report “World Preview 2018, Outlook to 2024” pointed out that Abbott Biotech drug Adalimumab will still defend the world’s best-selling drug list winner in 2024. Novartis will surpass Pfizer and Roche in 2024 to become the world’s largest prescription drug company with US$53.2 billion in revenue. In the increasingly… Continue Reading In 2024, the best-selling pharmaceutical company TOP10

The data displayed by Mercury‚Äôs I-O star Keytruda on the ASCO 2018 is amazing, and almost everyone believes that Keytruda has no doubt seized the throne of lung immunotherapy. However, competitors do not seem to agree with this. In their view, the difference between their drug and Keytruda is very… Continue Reading What is the difference between the PD-1/PD-L1 drugs in Merck, BMS, and Roche?

The fanaticism in the PD-1/PD-L1 field is a visible fact. Even clinical recruiters jokingly said that patients were not enough soon enough…. Is there any chance for latecomers in this field? The reporter recently also interviewed experts in this area. Intense competition Currently, there are 5 PD-1/PD-L1 inhibitors in the… Continue Reading Do PD-1/PD-L1 Latecomers Still Have Opportunities?

With the help of the revolutionary Hepatitis C drug Solvadi, Gilead has become the world’s top10 biopharmaceutical giant with a market value that exceeds Lilly and AstraZeneca. After Hepatitis C was cured, the larger Hepatitis B population became the next target for the pharmaceutical industry.   Unlike Hepatitis C, Hepatitis… Continue Reading Global hepatitis B drug R & D pipeline

On April 27, Roche announced that Roche and its holding company, Foundation Medicine, Inc., have signed a cooperation agreement with Dean Diagnostic Technology Group Co., Ltd. (hereinafter referred to as “Dean Diagnostics”). They will work together to promote the individualized treatment of cancer in China. According to the cooperation agreement,… Continue Reading Roche inspected Dean’s diagnosis and introduced “general genomic sequencing analysis service” to jointly promote the individualized diagnosis and treatment of Chinese tumors.